
Blake A. Morrison, PharmD, vice president, Medical and Scientific Affairs, Multiple Myeloma Research Foundation, discusses adverse events associated with new agents to treat patients with multiple myeloma.
Blake A. Morrison, PharmD, vice president, Medical and Scientific Affairs, Multiple Myeloma Research Foundation, discusses adverse events associated with new agents to treat patients with multiple myeloma.
Published: February 9th 2016 | Updated: